Evidence map›Paper›PMID 36920956›Full record

Observational studyPloS one2023

Process description of developing HIV prevention monitoring indicators for a province-wide pre-exposure prophylaxis (PrEP) program in British Columbia, Canada.

Lalani L Munasinghe, Junine Toy, Katherine J Lepik, David M Moore, Mark Hull, Nic Bacani, Paul Sereda, Rolando Barrios, Julio S G Montaner, Viviane D Lima

Open access · goldFull text readObservational Study
In one paragraph

Observational study in PloS one, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Lalani L MunasingheBritish Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada.ORCID 0000-0001-5859-9579
Junine ToyBritish Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada.
Katherine J LepikBritish Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada.ORCID 0000-0002-8358-8529
David M MooreBritish Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada.
Mark HullBritish Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada.
Nic BacaniBritish Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada.
Paul SeredaBritish Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada.ORCID 0000-0002-6411-8089
Rolando BarriosBritish Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada.
Julio S G MontanerBritish Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada.
Viviane D LimaBritish Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada.ORCID 0000-0003-4943-091X
AIDS Vancouver · CAUniversity of British Columbia · CASt. Paul's Hospital · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In 2018, the pre-exposure prophylaxis (PrEP) program was initiated in British Columbia (BC), Canada, providing PrEP at no cost to qualifying residents. This observational study discussed the steps to develop key evidence-based monitoring indicators and their calculation using real-time data. The indicators were conceptualized, developed, assessed and approved by the Technical Monitoring Committee of representatives from five health authority regions in BC, the BC Ministry of Health, the BC Centre for Disease Control, and the BC Centre for Excellence in HIV/AIDS. Indicator development followed the steps adopted from the United States Centers for Disease Control and Prevention framework for program evaluation in public health. The assessment involved eight selection criteria: data quality, indicator validity, existing scientific evidence, indicator informativeness, indicator computing feasibility, clients' confidentiality maintenance capacity, indicator accuracy, and administrative considerations. Clients' data from the provincial-wide PrEP program (January 2018-December 2020) shows the indicators' calculation. The finalized 14 indicators included gender, age, health authority, new clients enrolled by provider type and by the health authority, new clients dispensed PrEP, clients per provider, key qualifying HIV risk factor(s), client status, PrEP usage type, PrEP quantity dispensed, syphilis and HIV testing and incident cases, and adverse drug reaction events. Cumulative clients' data (n = 6966; 99% cis-gender males) identified an increased new client enrollment and an unexpected drop during the COVID-19 pandemic. About 80% dispensed PrEP from the Vancouver Coastal health authority. The HIV incidence risk index for men who have sex with men score ≥10 was the most common qualifying risk factor. The framework we developed integrating indicators was applied to monitor our PrEP program, which could help reduce the public health impact of HIV.

Indexed as

Acquired Immunodeficiency SyndromeAnti-HIV AgentsCOVID-19HIV InfectionsPre-Exposure ProphylaxisSexual and Gender MinoritiesBritish ColumbiaHomosexuality, MaleHumansMalePandemicsAnti-HIV Agents

Identifiers

PMID36920956
PMCPMC10016663
OpenAlexW4324311123

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read22
identifiers read3
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.